Efficacy and Safety of Qushi Huayu Granule for Hyperlipidemia: Study Protocol for a Randomized, Double-blind, Placebo-controlled Trial

Overview

Journal Trials

Publisher Biomed Central

Specialties General Medicine
Pharmacology

Date 2022 Feb 3

PMID 35109888

Authors

Yuanlong Sun

Na Hu

Gaofeng Chen

Yanjie Wang

Yiyang Hu

Maojun Ge

Yu Zhao

Affiliations

Soon will be listed here.

Abstract

Background: Hyperlipidemia has become a common chronic disease worldwide in recent years. Studies have shown that hyperlipidemia patients, especially those with a high level of serum low-density lipoprotein cholesterol (LDL-C), have a significantly higher prevalence of atherosclerosis, leading to coronary heart disease. Previous basic experiments and clinical studies have shown that Qushi Huayu granules (QSHY) reduce blood lipids in patients with non-alcoholic fatty liver disease (NAFLD) accompanied by hyperlipidemia. However, the clinical efficacy of QSHY in patients with hyperlipidemia is still lacking. This study aims to investigate the effect and safety of QSHY for hyperlipidemia.

Methods: This is a randomized, double-blind, placebo-controlled trial. A total of 210 participants will be enrolled and randomized into the QSHY or placebo granules groups in equal proportions, who will receive treatment for 24 weeks. The primary outcome will be the change in LDL-C from baseline to week 12. Secondary outcomes will be changes in other serum lipids markers, life quality measuring health surveys, and traditional Chinese medicine (TCM) pattern scale. All related tests will be measured at baseline, week 12, and week 24 after enrollment. Adverse events and the safety of intervention will be monitored and evaluated.

Discussion: We designed a clinical trial of hyperlipidemia management with QSHY, a TCM prescription. The results of this trial will present the efficacy and safety of QSHY in patients with hyperlipidemia.

Trial Registration: Chinese Clinical Trial Registry ChiCTR2000034125 . Registered on June 25, 2019.

References

Arnesen K, Phung A, Randsborg K, Mork I, Thorvall M, Langslet G . Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study. Front Pharmacol. 2021; 11:560958. PMC: 7961401. DOI: 10.3389/fphar.2020.560958. View

Volgman A, Palaniappan L, Aggarwal N, Gupta M, Khandelwal A, Krishnan A . Atherosclerotic Cardiovascular Disease in South Asians in the United States: Epidemiology, Risk Factors, and Treatments: A Scientific Statement From the American Heart Association. Circulation. 2018; 138(1):e1-e34. DOI: 10.1161/CIR.0000000000000580. View

McEvoy J, Blumenthal R, Blaha M . Statin therapy for hyperlipidemia. JAMA. 2013; 310(11):1184-5. DOI: 10.1001/jama.2013.276734. View

Hegele R, Ginsberg H, Chapman M, Nordestgaard B, Kuivenhoven J, Averna M . The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014; 2(8):655-66. PMC: 4201123. DOI: 10.1016/S2213-8587(13)70191-8. View

Laufs U, Parhofer K, Ginsberg H, Hegele R . Clinical review on triglycerides. Eur Heart J. 2019; 41(1):99-109c. PMC: 6938588. DOI: 10.1093/eurheartj/ehz785. View

Mohamed M, Salameh O, Saeed A . Statin-Induced Rhabdomyolysis, Acute Kidney Injury, and Hepatitis Leading to Death. Am J Case Rep. 2019; 20:709-712. PMC: 6537756. DOI: 10.12659/AJCR.914707. View

Zhang L, Zhang J, Feng R, Jin X, Yang F, Ji Z . Efficacy and Safety of Berberine Alone or Combined with Statins for the Treatment of Hyperlipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. Am J Chin Med. 2019; 47(4):751-767. DOI: 10.1142/S0192415X19500393. View

Schmitz G, Orso E . Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects. Clin Res Cardiol Suppl. 2015; 10:21-5. PMC: 4361722. DOI: 10.1007/s11789-015-0074-0. View

Walsh J, Pignone M . Drug treatment of hyperlipidemia in women. JAMA. 2004; 291(18):2243-52. DOI: 10.1001/jama.291.18.2243. View

10.

Gou X, Gao S, Chen L, Feng Q, Hu Y . A Metabolomic Study on the Intervention of Traditional Chinese Medicine Qushi Huayu Decoction on Rat Model of Fatty Liver Induced by High-Fat Diet. Biomed Res Int. 2019; 2019:5920485. PMC: 6383432. DOI: 10.1155/2019/5920485. View

11.

Bellosta S, Corsini A . Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2017; 17(1):25-37. DOI: 10.1080/14740338.2018.1394455. View

12.

Gou X, Feng Q, Fan L, Zhu J, Hu Y . Serum and Liver Tissue Metabonomic Study on Fatty Liver in Rats Induced by High-Fat Diet and Intervention Effects of Traditional Chinese Medicine Qushi Huayu Decoction. Evid Based Complement Alternat Med. 2017; 2017:6242697. PMC: 5605908. DOI: 10.1155/2017/6242697. View

13.

Sakamoto K, Kimura J . Mechanism of statin-induced rhabdomyolysis. J Pharmacol Sci. 2013; 123(4):289-94. DOI: 10.1254/jphs.13r06cp. View

14.

Lian X, Zhang Y, Li X, Jing L, Cairang Z, Gou J . Exploration on the relationship between the elderly osteoporosis and cardiovascular disease risk factors. Eur Rev Med Pharmacol Sci. 2017; 21(19):4386-4390. View

15.

Sharma P, Timilsina B, Adhikari J, Parajuli P, Dhital R, Tachamo N . Statin-induced necrotizing autoimmune myopathy: an extremely rare adverse effect from statin use. J Community Hosp Intern Med Perspect. 2020; 9(6):503-506. PMC: 6968631. DOI: 10.1080/20009666.2019.1702272. View

16.

Birnbaum R, Horton B, Gidding S, Brenman L, Macapinlac B, Avins A . Closing the gap: Identification and management of familial hypercholesterolemia in an integrated healthcare delivery system. J Clin Lipidol. 2021; 15(2):347-357. DOI: 10.1016/j.jacl.2021.01.008. View

17.

Moran A, Gu D, Zhao D, Coxson P, Wang Y, Chen C . Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china. Circ Cardiovasc Qual Outcomes. 2010; 3(3):243-52. PMC: 2937540. DOI: 10.1161/CIRCOUTCOMES.109.910711. View

18.

Li Y, Chao T, Liu P, Ueng K, Yeh H . Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients. Acta Cardiol Sin. 2018; 34(5):371-378. PMC: 6160516. DOI: 10.6515/ACS.201809_34(5).20180629A. View

19.

Zhao S, Liu L, Cheng Y, Shishehbor M, Liu M, Peng D . Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation. 2004; 110(8):915-20. DOI: 10.1161/01.CIR.0000139985.81163.CE. View

20.

Cybulsky M, Cook S, Kontsevaya A, Vasiljev M, Leon D . Pharmacological treatment of hypertension and hyperlipidemia in Izhevsk, Russia. BMC Cardiovasc Disord. 2016; 16:122. PMC: 4891885. DOI: 10.1186/s12872-016-0300-9. View